Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer

ISSN: 2212-3970 (Online)
ISSN: 1574-8928 (Print)

Volume 12, 4 Issues, 2017

Download PDF Flyer

Recent Patents on Anti-Cancer Drug Discovery

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 35th of 254 in Pharmacology & Pharmacy
  • 46th of 211 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Khurshid Zaman
Bentham Science Publishers

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.533
5 - Year: 2.638

Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer

Recent Patents on Anti-Cancer Drug Discovery, 9(3): 267-285.

Author(s): Marilena Manea, Marina Montagnani Marelli, Roberta M. Moretti, Roberto Maggi, Monica Marzagalli and Patrizia Limonta.

Affiliation: Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy.


It is now well established that hormonal pathways are involved in the development of prostate cancer towards the castration resistant (CRPC) stage and can be effective molecular targets for novel treatment strategies. Most CRPC are sensitive to androgens and this can be due to the intratumoral production of androgens, androgen receptor (AR) amplification/ mutations and epigenetic modifications of AR expression/signaling. Based on these observations, potent agents targeting the AR axis were developed: 1) inhibitors of CYP17 (a key enzyme in the production of androgens), such as abiraterone and orteronel; 2) AR antagonists that bind to AR and impair AR activation, such as enzalutamide and ARN-509. Moreover, gonadotropin-releasing hormone receptors (GnRH-R), associated with a strong antitumor activity, are expressed in CRPC cells, indicating that they might represent an important target for GnRH analog-based therapeutic strategies. In addition to GnRH agonists and antagonists (i.e., degarelix), cytotoxic GnRH-based bioconjugates, delivering chemotherapeutic drugs to cancer cells expressing the GnRH-R, were developed and reported to exert antitumor effects on CRPC cells; some of them (i.e., AN-152) have already entered clinical trials. This review discusses the most relevant patents and recent observations on the anti-cancer efficacy of novel drugs targeting the AR and the GnRH-R pathways in CRPC.


Androgens, androgen receptors (AR), androgen synthesis inhibitors, AR antagonists, cytotoxic GnRH-based hybrid compounds, gonadotropin-releasing hormone (GnRH), GnRH analogs, GnRH receptors (GnRH-R).

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 3
First Page: 267
Last Page: 285
Page Count: 19
DOI: 10.2174/1574892809666140520113953
Price: $100

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science